198 related articles for article (PubMed ID: 21558395)
1. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer.
Grimminger PP; Danenberg P; Dellas K; Arnold D; Rödel C; Machiels JP; Haustermans K; Debucquoy A; Velenik V; Sempoux C; Bracko M; Hölscher AH; Semrau R; Yang D; Danenberg K; Lenz HJ; Vallböhmer D
Clin Cancer Res; 2011 May; 17(10):3469-77. PubMed ID: 21558395
[TBL] [Abstract][Full Text] [Related]
2. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment transcriptional profiling for predicting response to neoadjuvant chemoradiotherapy in rectal adenocarcinoma.
Brettingham-Moore KH; Duong CP; Greenawalt DM; Heriot AG; Ellul J; Dow CA; Murray WK; Hicks RJ; Tjandra J; Chao M; Bui A; Joon DL; Thomas RJ; Phillips WA
Clin Cancer Res; 2011 May; 17(9):3039-47. PubMed ID: 21224373
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
[TBL] [Abstract][Full Text] [Related]
5. EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.
Hu-Lieskovan S; Vallbohmer D; Zhang W; Yang D; Pohl A; Labonte MJ; Grimminger PP; Hölscher AH; Semrau R; Arnold D; Dellas K; Debucquoy A; Haustermans K; Machiels JP; Sempoux C; Rödel C; Bracko M; Velenik V; Lenz HJ
Clin Cancer Res; 2011 Aug; 17(15):5161-9. PubMed ID: 21673069
[TBL] [Abstract][Full Text] [Related]
6. Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials.
Weiss C; Arnold D; Dellas K; Liersch T; Hipp M; Fietkau R; Sauer R; Hinke A; Rödel C
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):472-8. PubMed ID: 20133081
[TBL] [Abstract][Full Text] [Related]
7. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
[TBL] [Abstract][Full Text] [Related]
9. Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation.
Schneider S; Park DJ; Yang D; El-Khoueiry A; Sherrod A; Groshen S; Streeter O; Iqbal S; Danenberg KD; Lenz HJ
Pharmacogenet Genomics; 2006 Aug; 16(8):555-63. PubMed ID: 16847424
[TBL] [Abstract][Full Text] [Related]
10. Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.
Maus MK; Hanna DL; Stephens CL; Astrow SH; Yang D; Grimminger PP; Loupakis F; Hsiang JH; Zeger G; Wakatsuki T; Barzi A; Lenz HJ
Pharmacogenomics J; 2015 Aug; 15(4):354-62. PubMed ID: 25532759
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer.
Moureau-Zabotto L; Farnault B; de Chaisemartin C; Esterni B; Lelong B; Viret F; Giovannini M; Monges G; Delpero JR; Bories E; Turrini O; Viens P; Salem N
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):483-91. PubMed ID: 21093174
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.
Bertolini F; Chiara S; Bengala C; Antognoni P; Dealis C; Zironi S; Malavasi N; Scolaro T; Depenni R; Jovic G; Sonaglio C; Rossi A; Luppi G; Conte PF
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):466-72. PubMed ID: 19004567
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
Balboa E; Duran G; Lamas MJ; Gomez-Caamaño A; Celeiro-Muñoz C; Lopez R; Carracedo A; Barros F
Pharmacogenomics; 2010 Jun; 11(6):747-61. PubMed ID: 20504250
[TBL] [Abstract][Full Text] [Related]
15. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?
Kuo LJ; Liu MC; Jian JJ; Horng CF; Cheng TI; Chen CM; Fang WT; Chung YL
Ann Surg Oncol; 2007 Oct; 14(10):2766-72. PubMed ID: 17551794
[TBL] [Abstract][Full Text] [Related]
16. Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer.
Yang D; Schneider S; Azuma M; Iqbal S; El-Khoueiry A; Groshen S; Agafitei D; Danenberg KD; Danenberg PV; Ladner RD; Lenz HJ
Clin Colorectal Cancer; 2006 Nov; 6(4):305-11. PubMed ID: 17241515
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment expression of 13 molecular markers as a predictor of tumor responses after neoadjuvant chemoradiation in rectal cancer.
Huh JW; Lee JH; Kim HR
Ann Surg; 2014 Mar; 259(3):508-15. PubMed ID: 23787217
[TBL] [Abstract][Full Text] [Related]
18. Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer.
Katz MS; Minsky BD; Saltz LB; Riedel E; Chessin DB; Guillem JG
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1363-70. PubMed ID: 16029794
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer.
Velenik V; Ocvirk J; Oblak I; Anderluh F
Eur J Surg Oncol; 2010 Mar; 36(3):244-50. PubMed ID: 20042310
[TBL] [Abstract][Full Text] [Related]
20. XRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer.
Grimminger PP; Brabender J; Warnecke-Eberz U; Narumiya K; Wandhöfer C; Drebber U; Bollschweiler E; Hölscher AH; Metzger R; Vallböhmer D
J Surg Res; 2010 Nov; 164(1):e61-6. PubMed ID: 20863523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
